ReviewCNS drugs2012
A comprehensive review of rapid-onset opioids for breakthrough pain.
Review in CNS drugs, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- The Impact of Massage Therapy on Function in Pain Populations-A Systematic Review and Meta-Analysis of Randomized Controlled Trials: Part II, Cancer Pain Populations.Pain medicine (Malden, Mass.) · 2016Pooled it
- Distraction Technique for pain reduction in Peripheral Venous Catheterization: randomized, controlled trial.Acta bio-medica : Atenei Parmensis · 2018Trial
- Trial
- Breakthrough pain and rapid-onset opioids in patients with cancer pain: a narrative review.Journal of Yeungnam medical science · 2024Article
- Immediate release fentanyl in general practices: Mostly off-label prescribing.The European journal of general practice · 2023Article
- Public health and medical preparedness for mass casualties from the deliberate release of synthetic opioids.Frontiers in public health · 2023Article
- Fentanyl in cancer pain management: avoiding hasty judgments and discerning its potential benefits.Drugs in context · 2023Review
- The Burden of Metastatic Cancer-Induced Bone Pain: A Narrative Review.Journal of pain research · 2022Review
- Rapid-Onset Opioids for Management of Breakthrough Cancer Pain: Considerations for Daily Practice.Frontiers in pain research (Lausanne, Switzerland) · 2022Review
- Transmucosal drug administration as an alternative route in palliative and end-of-life care during the COVID-19 pandemic.Advanced drug delivery reviews · 2020Review
- Working towards a consensus on the oncological approach of breakthrough pain: a Delphi survey of Spanish experts.Journal of pain research · 2019Article
- Review
- Addressing Opioid-Related Chemical Coping in Long-Term Opioid Therapy for Chronic Noncancer Pain: A Multicenter, Observational, Cross-Sectional Study.Journal of clinical medicine · 2018Article
- Fentanyl buccal tablet for breakthrough cancer pain in clinical practice: results of the non-interventional prospective study ErkentNIS.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2018Article
- Review
- Opioids Resistance in Chronic Pain Management.Current neuropharmacology · 2017Review
- Review
- A new splice of life for the μ-opioid receptor.The Journal of clinical investigation · 2015Article
- Safety profile of intravenous patient-controlled analgesia for breakthrough pain in cancer patients: a case series study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2014Article
- Pre-emptive small dose of fentanyl suppresses fentanyl-induced cough: a meta-analysis of randomized controlled trials.International journal of clinical and experimental medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breakthrough pain (BTP) is a transitory pain (reaching maximum severity in ~15 minutes and lasting ~60 minutes in patients with cancer) that occurs despite the management of chronic pain with long-term around-the-clock analgesia. BTP occurs in 33-65% of patients with chronic cancer pain and in ~70% of patients with chronic noncancer pain. BTP has historically been managed with short-acting opioids; however, these medications have a pharmacokinetic profile that does not correlate with the sudden onset and short time to maximum severity of BTP. Interest in rapid-onset opioids to relieve BTP has therefore been growing. This comprehensive review aims to summarize the currently available clinical data for the approved rapid-onset opioids, which comprise different formulations of fentanyl, a μ-opioid receptor agonist with anaesthetic and analgesic properties. Administration routes for fentanyl in the management of BTP currently include the transmucosal and intranasal routes; an intrapulmonary formulation is also in development. The findings of this review suggest that the efficacy and safety of the approved rapid-onset opioids are comparable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.